For primary hyperlipidemia. ANDA 91600, held by Impax Labs Inc. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 91600 (Colesevelam Hydrochloride), held by Impax Labs Inc, was first approved by FDA on May 16, 2018, with 4 approved supplements and 0 published complete response letters.
Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification. Limitations of Use: Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 16, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Rx |
| Oct 11, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 16, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters